HC Wainwright restated their buy rating on shares of Rani Therapeutics (NASDAQ:RANI - Free Report) in a report released on Thursday morning,Benzinga reports. The firm currently has a $9.00 price target on the stock.
Separately, Canaccord Genuity Group reissued a "buy" rating and issued a $9.00 price objective on shares of Rani Therapeutics in a research report on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Rani Therapeutics currently has a consensus rating of "Buy" and an average target price of $12.33.
View Our Latest Analysis on Rani Therapeutics
Rani Therapeutics Stock Up 2.7 %
RANI traded up $0.03 on Thursday, hitting $1.15. 99,526 shares of the company were exchanged, compared to its average volume of 747,084. The stock's fifty day moving average is $1.49 and its 200-day moving average is $1.79. Rani Therapeutics has a 12 month low of $1.03 and a 12 month high of $8.75. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60. The company has a market cap of $65.88 million, a PE ratio of -1.08 and a beta of 0.24.
Rani Therapeutics (NASDAQ:RANI - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). The firm had revenue of $1.03 million during the quarter. Equities research analysts predict that Rani Therapeutics will post -1.01 EPS for the current fiscal year.
Institutional Investors Weigh In On Rani Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC bought a new position in shares of Rani Therapeutics in the fourth quarter valued at about $37,000. Virtu Financial LLC acquired a new position in Rani Therapeutics in the 4th quarter valued at about $62,000. Insigneo Advisory Services LLC bought a new position in Rani Therapeutics in the 4th quarter valued at about $65,000. Two Sigma Advisers LP acquired a new stake in Rani Therapeutics during the fourth quarter worth approximately $151,000. Finally, Takeda Pharmaceutical Co. Ltd. acquired a new stake in Rani Therapeutics during the fourth quarter worth approximately $278,000. Institutional investors and hedge funds own 30.19% of the company's stock.
Rani Therapeutics Company Profile
(
Get Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
See Also
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
